Kawasaki, Japan

Toshihiro Hatanaka

This inventor holds 18 USPTO granted patents. Top assignee: Ajinomoto Co., Ltd.. Active years: 1997-2015.


% Patents Active = 5.6

Average Co-Inventor Count = 8.7

ph-index = 6

Forward Citations = 160(Granted Patents)


Company Filing History:


Years Active: 1997-2015

Loading Chart...
18 patents (USPTO):Explore Patents

Title: The Innovations of Toshihiro Hatanaka

Introduction

Toshihiro Hatanaka is a prominent inventor based in Kawasaki, Japan. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that exhibit CaSR agonistic activity. With a total of 18 patents to his name, Hatanaka's work has the potential to impact various therapeutic areas.

Latest Patents

Hatanaka's latest patents focus on CaSR agonists. By searching for various compounds that possess CaSR agonistic activity, he has developed agents that can be used in pharmaceutical compositions. These agents serve as preventive or therapeutic solutions for diarrhea and kokumi-imparting agents. More specifically, his inventions include glutamic acid derivatives that exhibit CaSR agonistic activity or their pharmaceutically acceptable salts.

Career Highlights

Hatanaka is associated with Ajinomoto Co., Ltd., a leading company in the food and pharmaceutical industries. His work at Ajinomoto has allowed him to explore innovative solutions that address health-related issues through the development of new compounds.

Collaborations

Hatanaka has collaborated with notable colleagues, including Nobuo Kondo and Hiroyuki Matsueda. These collaborations have further enriched his research and development efforts, leading to advancements in the field.

Conclusion

Toshihiro Hatanaka's contributions to the field of pharmaceutical sciences through his innovative patents highlight his role as a key inventor. His work continues to pave the way for new therapeutic agents that can improve health outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…